128 related articles for article (PubMed ID: 22052452)
1. Ronacaleret, a calcium-sensing receptor antagonist, increases trabecular but not cortical bone in postmenopausal women.
Fitzpatrick LA; Dabrowski CE; Cicconetti G; Gordon DN; Fuerst T; Engelke K; Genant HK
J Bone Miner Res; 2012 Feb; 27(2):255-62. PubMed ID: 22052452
[TBL] [Abstract][Full Text] [Related]
2. The effects of ronacaleret, a calcium-sensing receptor antagonist, on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mineral density.
Fitzpatrick LA; Dabrowski CE; Cicconetti G; Gordon DN; Papapoulos S; Bone HG; Bilezikian JP
J Clin Endocrinol Metab; 2011 Aug; 96(8):2441-9. PubMed ID: 21593114
[TBL] [Abstract][Full Text] [Related]
3. Bone mineral density changes following discontinuation of ronacaleret treatment: off-treatment extension of a randomized, dose-finding phase II trial.
Fitzpatrick LA; Wooddell M; Dabrowski CE; Cicconetti G; Gordon DN
Bone; 2014 Oct; 67():104-8. PubMed ID: 24794093
[TBL] [Abstract][Full Text] [Related]
4. Characterization of the effect of chronic administration of a calcium-sensing receptor antagonist, ronacaleret, on renal calcium excretion and serum calcium in postmenopausal women.
Caltabiano S; Dollery CT; Hossain M; Kurtinecz MT; Desjardins JP; Favus MJ; Kumar R; Fitzpatrick LA
Bone; 2013 Sep; 56(1):154-62. PubMed ID: 23756230
[TBL] [Abstract][Full Text] [Related]
5. Ronacaleret, a calcium-sensing receptor antagonist, has no significant effect on radial fracture healing time: results of a randomized, double-blinded, placebo-controlled Phase II clinical trial.
Fitzpatrick LA; Smith PL; McBride TA; Fries MA; Hossain M; Dabrowski CE; Gordon DN
Bone; 2011 Oct; 49(4):845-52. PubMed ID: 21742071
[TBL] [Abstract][Full Text] [Related]
6. Effects of Romosozumab Compared With Teriparatide on Bone Density and Mass at the Spine and Hip in Postmenopausal Women With Low Bone Mass.
Genant HK; Engelke K; Bolognese MA; Mautalen C; Brown JP; Recknor C; Goemaere S; Fuerst T; Yang YC; Grauer A; Libanati C
J Bone Miner Res; 2017 Jan; 32(1):181-187. PubMed ID: 27487526
[TBL] [Abstract][Full Text] [Related]
7. Odanacatib treatment affects trabecular and cortical bone in the femur of postmenopausal women: results of a two-year placebo-controlled trial.
Engelke K; Fuerst T; Dardzinski B; Kornak J; Ather S; Genant HK; de Papp A
J Bone Miner Res; 2015 Jan; 30(1):30-8. PubMed ID: 24898537
[TBL] [Abstract][Full Text] [Related]
8. Femoral strength in osteoporotic women treated with teriparatide or alendronate.
Keaveny TM; McClung MR; Wan X; Kopperdahl DL; Mitlak BH; Krohn K
Bone; 2012 Jan; 50(1):165-70. PubMed ID: 22015818
[TBL] [Abstract][Full Text] [Related]
9. Short-term changes in bone turnover markers and bone mineral density response to parathyroid hormone in postmenopausal women with osteoporosis.
Bauer DC; Garnero P; Bilezikian JP; Greenspan SL; Ensrud KE; Rosen CJ; Palermo L; Black DM
J Clin Endocrinol Metab; 2006 Apr; 91(4):1370-5. PubMed ID: 16449339
[TBL] [Abstract][Full Text] [Related]
10. Bone density, turnover, and estimated strength in postmenopausal women treated with odanacatib: a randomized trial.
Brixen K; Chapurlat R; Cheung AM; Keaveny TM; Fuerst T; Engelke K; Recker R; Dardzinski B; Verbruggen N; Ather S; Rosenberg E; de Papp AE
J Clin Endocrinol Metab; 2013 Feb; 98(2):571-80. PubMed ID: 23337728
[TBL] [Abstract][Full Text] [Related]
11. Hip and spine strength effects of adding versus switching to teriparatide in postmenopausal women with osteoporosis treated with prior alendronate or raloxifene.
Cosman F; Keaveny TM; Kopperdahl D; Wermers RA; Wan X; Krohn KD; Krege JH
J Bone Miner Res; 2013 Jun; 28(6):1328-36. PubMed ID: 23281041
[TBL] [Abstract][Full Text] [Related]
12. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis.
Black DM; Greenspan SL; Ensrud KE; Palermo L; McGowan JA; Lang TF; Garnero P; Bouxsein ML; Bilezikian JP; Rosen CJ;
N Engl J Med; 2003 Sep; 349(13):1207-15. PubMed ID: 14500804
[TBL] [Abstract][Full Text] [Related]
13. Effects of odanacatib on the radius and tibia of postmenopausal women: improvements in bone geometry, microarchitecture, and estimated bone strength.
Cheung AM; Majumdar S; Brixen K; Chapurlat R; Fuerst T; Engelke K; Dardzinski B; Cabal A; Verbruggen N; Ather S; Rosenberg E; de Papp AE
J Bone Miner Res; 2014 Aug; 29(8):1786-94. PubMed ID: 24643905
[TBL] [Abstract][Full Text] [Related]
14. A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis.
Body JJ; Gaich GA; Scheele WH; Kulkarni PM; Miller PD; Peretz A; Dore RK; Correa-Rotter R; Papaioannou A; Cumming DC; Hodsman AB
J Clin Endocrinol Metab; 2002 Oct; 87(10):4528-35. PubMed ID: 12364430
[TBL] [Abstract][Full Text] [Related]
15. The effect of the cathepsin K inhibitor ONO-5334 on trabecular and cortical bone in postmenopausal osteoporosis: the OCEAN study.
Engelke K; Nagase S; Fuerst T; Small M; Kuwayama T; Deacon S; Eastell R; Genant HK
J Bone Miner Res; 2014 Mar; 29(3):629-38. PubMed ID: 24038152
[TBL] [Abstract][Full Text] [Related]
16. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate.
Ettinger B; San Martin J; Crans G; Pavo I
J Bone Miner Res; 2004 May; 19(5):745-51. PubMed ID: 15068497
[TBL] [Abstract][Full Text] [Related]
17. An orally active calcium-sensing receptor antagonist that transiently increases plasma concentrations of PTH and stimulates bone formation.
Kumar S; Matheny CJ; Hoffman SJ; Marquis RW; Schultz M; Liang X; Vasko JA; Stroup GB; Vaden VR; Haley H; Fox J; DelMar EG; Nemeth EF; Lago AM; Callahan JF; Bhatnagar P; Huffman WF; Gowen M; Yi B; Danoff TM; Fitzpatrick LA
Bone; 2010 Feb; 46(2):534-42. PubMed ID: 19786130
[TBL] [Abstract][Full Text] [Related]
18. Effects of four-year cyclic versus two-year daily teriparatide treatment on volumetric bone density and bone strength in postmenopausal women with osteoporosis.
Ganapathy A; Nieves JW; Keaveny TM; Cosman F
Bone; 2023 Feb; 167():116618. PubMed ID: 36410666
[TBL] [Abstract][Full Text] [Related]
19. Denosumab improves density and strength parameters as measured by QCT of the radius in postmenopausal women with low bone mineral density.
Genant HK; Engelke K; Hanley DA; Brown JP; Omizo M; Bone HG; Kivitz AJ; Fuerst T; Wang H; Austin M; Libanati C
Bone; 2010 Jul; 47(1):131-9. PubMed ID: 20399288
[TBL] [Abstract][Full Text] [Related]
20. Improvements in hip trabecular, subcortical, and cortical density and mass in postmenopausal women with osteoporosis treated with denosumab.
Genant HK; Libanati C; Engelke K; Zanchetta JR; Høiseth A; Yuen CK; Stonkus S; Bolognese MA; Franek E; Fuerst T; Radcliffe HS; McClung MR
Bone; 2013 Oct; 56(2):482-8. PubMed ID: 23871852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
